SIGLEC5 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O15389 |
---|---|
Clone Names | 100617107 |
Gene ID | 8778 |
---|---|
Other Names | Sialic acid-binding Ig-like lectin 5, Siglec-5, CD33 antigen-like 2, Obesity-binding protein 2, OB-BP2, OB-binding protein 2, CD170, SIGLEC5, CD33L2, OBBP2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | SIGLEC5 |
---|---|
Synonyms | CD33L2, OBBP2 |
Function | Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds equally to alpha-2,3-linked and alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. |
Cellular Location | Membrane; Single-pass type I membrane protein. |
Tissue Location | Expressed by monocytic/myeloid lineage cells. Found at high levels in peripheral blood leukocytes, spleen, bone marrow and at lower levels in lymph node, lung, appendix, placenta, pancreas and thymus. Expressed by monocytes and neutrophils but absent from leukemic cell lines representing early stages of myelomonocytic differentiation |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The sialic acid-binding immunoglobulin-like lectins(SIGLECs), such as SIGLEC5, are a subgroup of the immunoglobulin(Ig) superfamily that mediate protein-carbohydrate interactions.They specifically interact with sialic acids in glycoproteins andglycolipids, with each SIGLEC having a particular preference forboth the nature of the sialic acid and its glycosidic linkage toadjacent sugars. SIGLECs have similar structures, includingextracellular Ig-like domains composed of an N-terminal V-setdomain followed by varying numbers of C2-set domains. It appearsthat all SIGLECs have an unusual arrangement of conserved cysteineresidues in the V-set and adjacent C2-set domains. Most SIGLECs areexpressed uniquely within the hematopoietic system (Cornish et al.,1998 [PubMed 9731071]).
References
Soto, P.C., et al. J. Immunol. 184(8):4185-4195(2010)Davila, S., et al. Genes Immun. 11(3):232-238(2010)Carlin, A.F., et al. J. Exp. Med. 206(8):1691-1699(2009)Zhuravleva, M.A., et al. J. Mol. Biol. 375(2):437-447(2008)Gunnarsson, P., et al. FASEB J. 21(14):4059-4069(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.